Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
06/15/2018 06/18/2018 06/19/2018 06/20/2018 06/21/2018 Date
0.3385(c) 0.334(c) 0.335(c) 0.326(c) 0.365 Last
614 964 574 549 411 528 431 449 3 237 326 Volume
-2.45% -1.33% +0.30% -2.69% +11.96% Change
More quotes
Financials (EUR)
Sales 2018 8,00 M
EBIT 2018 -7,03 M
Net income 2018 -8,06 M
Finance 2018 25,8 M
Yield 2018 -
Sales 2019 9,73 M
EBIT 2019 -4,02 M
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,53x
Capi. / Sales2019 3,09x
Capitalization 30,0 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Latest news on NEOVACS
05/15NEOVACS : Strengthens intellectual property position in europe...
PU
05/15NEOVACS : Strengthens intellectual property position in europe and japan
GL
05/15NEOVACS : Strengthens intellectual property position in europe and japan
AQ
03/30NEOVACS : Provides corporate update and reports full-year 2017 financial results
GL
03/30NEOVACS : Provides corporate update and reports full-year 2017 financial results
AQ
03/27NEOVACS SA : annual earnings release
03/13NEOVACS : Phase 2b Trial of Neovacs Investigational Lupus Immunotherapy on Track..
AQ
02/22NEOVACS : Strengthens its intellectual property in the usa
GL
02/16NEOVACS : 2018 Financial Calendar
GL
02/14NEOVACS : Announces Positive Data Review from Last IDSMB Review Prior to Final R..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/12Zacks - SBOT: Neovacs Ph2 Lupus Results Expected Next Month, Could Represent .. 
03/30NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017 FINANCIAL RESULT.. 
02/13Neovacs : Announces Positive Data Review from Last IDSMB Review Prior to Fina.. 
2017NEOVACS : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR...  
2017Neovacs : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID.. 
More tweets
Qtime:33
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,48 €
Spread / Average Target 355%
EPS Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
Daniel Zagury Director
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-29.13%35
CELLTRION, INC.--.--%33 593
IQVIA HOLDINGS INC7.88%21 859
LONZA GROUP2.81%19 855
INCYTE CORPORATION-22.94%15 470
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 517